Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers

Summary

2-DG-01 is a randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study assessing safety, tolerability and pharmacokinetics of 2-DG in normal healthy volunteers (NHV). The safety and pharmacokinetics of 2-DG are assessed after single or multiple intranasal administrations.

Timeline

Start

2022-03-03

Primary completion

2023-08-01

Completion

2023-09-27

Publications

• Bischof T, Gsoellpointner M, Miljevic KDK, Moser MM, Dizdarevic AM, Gualdoni GA, Gorki AD, Nicolodi C, Chou S, Radivojev S, Haiden N, Mueller CA, Firbas C, Jilma B, Schoergenhofer C. Safety, tolerability, and pharmacokinetics of intranasal 2-deoxy-D-glucose in normal healthy volunteers: A randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study. Eur J Pharm Sci. 2025 Jun 1;209:107069. doi: 10.1016/j.ejps.2025.107069. Epub 2025 Mar 16.

Drugs

Indications